Leukemia Clinical Trials in Tianjin, Tianjin Municipality

58 recruitingTianjin, Tianjin Municipality, China

Showing 120 of 58 trials

Recruiting
Phase 1Phase 2

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines614 enrolled120 locationsNCT05006716
Recruiting
Phase 3

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Merck Sharp & Dohme LLC1,200 enrolled195 locationsNCT06136559
Recruiting
Phase 1Phase 2

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

B Cell Precursor Acute Lymphoblastic Leukemia
Amgen281 enrolled86 locationsNCT04521231
Recruiting
Phase 1Phase 2

A Study of BGB-11417 in Participants With Myeloid Malignancies

Acute Myeloid LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasm
BeiGene260 enrolled46 locationsNCT04771130
Recruiting
Phase 1

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

Acute Myelogenous LeukemiaMyelodysplastic Syndromes (MDS)
Beijing InnoCare Pharma Tech Co., Ltd.266 enrolled15 locationsNCT06656494
Recruiting
Phase 1Phase 2

A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)

Acute Lymphoblastic Leukemia
MSD R&D (China) Co., Ltd.203 enrolled11 locationsNCT05579132
Recruiting

National Longitudinal Cohort of Hematological Diseases

Acute Myeloid LeukemiaMultiple MyelomaMyelodysplastic Syndrome+14 more
Institute of Hematology & Blood Diseases Hospital, China2,300 enrolled1 locationNCT04645199
Recruiting
Not Applicable

Using Mobile Technology-assisted Outpatient Maintenance Therapy Pediatric ALL

Pediatric Acute Leukemia
Institute of Hematology & Blood Diseases Hospital, China200 enrolled1 locationNCT07278882
Recruiting
Phase 3

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
BeOne Medicines150 enrolled64 locationsNCT06970743
Recruiting
Early Phase 1

A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia

Chronic Lymphocytic Leukemia (CLL)B-cell Acute Lymphoblastic Leukemia (B-ALL)Autoimmune Hemolytic Anemia, AIHA+1 more
Grit Biotechnology28 enrolled2 locationsNCT07205315
Recruiting
Phase 2

A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
AbbVie110 enrolled31 locationsNCT02966756
Recruiting
Phase 1Phase 2

SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies

Acute Myeloid Leukemia (AML)T Lymphoblastic Leukemia/Lymphoma
Institute of Hematology & Blood Diseases Hospital, China12 enrolled1 locationNCT07153068
Recruiting
Phase 2

Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML

AML (Acute Myeloid Leukemia)Allogeneic Hematopoietic Cell Transplantation (HCT)
Institute of Hematology & Blood Diseases Hospital, China134 enrolled5 locationsNCT07304232
Recruiting
Phase 2

Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Institute of Hematology & Blood Diseases Hospital, China53 enrolled1 locationNCT06387121
Recruiting
Phase 2

PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma

CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.100 enrolled15 locationsNCT07188610
Recruiting
Phase 2

DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Dizal Pharmaceuticals155 enrolled17 locationsNCT06539182
Recruiting
Phase 3

IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)

Chronic Myelomonocytic Leukemia
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.170 enrolled43 locationsNCT06647862
Recruiting
Phase 3

A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia

Acute Myeloid Leukemia
Ascentage Pharma Group Inc.486 enrolled6 locationsNCT06389292
Recruiting
Phase 3

A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Dizal (Jiangsu) Pharmaceutical Co., Ltd.250 enrolled2 locationsNCT07139873
Recruiting
Phase 2

Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia

T-LGL LeukemiaNK-LGL Leukemia
Institute of Hematology & Blood Diseases Hospital, China48 enrolled1 locationNCT06530576